Logan Coy Related postsA Phase 1b study of the pharmacokinetics, safety, and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemiaSeptember 11, 2026A Phase 2, Randomized, Open-label Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic SyndromeSeptember 11, 2026A Single-arm, Open-label, Phase 2 Study of Subcutaneous Isatuximab via On-Body Delivery System with Weekly Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)September 11, 2026 Previous postA Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsNext postA Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study of Topical HT-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitor